Hansa Medical acquires rights to cancer immunotherapy using antibody-modulating enzymes
The founders of Immago Biosystems, Dr Chris Scanlan and Dr Max Crispin at the Glycoprotein Therapeutics Laboratory, at the University of Oxford, have discovered that IgG-antibody modulating enzymes can enhance the efficacy of antibody based cancer treatments. Together with their colleague, Dr Kavitha Baruah, they formed Immago Biosystems Ltd to help bring these concepts to the clinic. Immago Biosystems has applied for patent protection for this concept, and the research results have subsequently been published in the Journal of Molecular Biology, 2012 Jun 29;420(1-2):1-7.
Hansa Medical has recently verified the research findings by combining its lead candidate IdeS with approved anti-cancer antibodies in preclinical cancer models, and has applied for further patent protection in this area.
“By combining IdeS with a therapeutic antibody, the in vitro and in vivo efficacy of the antibody is significantly enhanced with maintained specificity. Potentially, this means that presently available antibody based cancer therapies could be made more effective”, commented Dr Christian Kjellman, Senior Vice President, R&D at Hansa Medical AB.
“Our verification of the research findings by Immago has encouraged us to further examine the potential of IdeS and EndoS within cancer immunotherapy. Although the findings are to be regarded as early preclinical research findings, we believe that this concept can hold significant potential for IdeS and EndoS in addition to the focus of our current clinical program in transplantation and autoimmunity,” said Göran Arvidson, CEO of Hansa Medical AB.
The global market for monoclonal antibodies (mAbs) for cancer is estimated at $23 billion, and is expected to grow to $33 billion by 2017, according to Cancer Monoclonal Antibodies Market Forecast to 2017 (August 13, 2013).
The sum of the acquisition was not disclosed. The acquisition will not have a significant impact on the Hansa Medical result for 2016.
The information in this press release is disclosed pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person stated below on July 19, 2016 at 13.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: 46 70-633 30 42